

Rev 02/07

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : Laszlo Takacs et al.  
Application No. : 10/588,392  
Filed : August 03, 2006  
Confirmation No. : 8285  
For : MONOCLONAL ANTIBODY BASED BIOMARKER  
DISCOVERY AND DEVELOPMENT PLATFORM  
Examiner : Jeffrey S. Lundgren  
Attorney's Docket : NU-BI-659XX

TC Art Unit: 1639

RESPONSE TO RESTRICTION REQUIREMENT***Via EFS-Web***

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Restriction Requirement dated August 11, 2008, Applicants hereby elect Group I, with traverse, for prosecution at this time. The species elected for search purposes are:

- A. the *selecting* step - claim 2
- B. the *pretreatment* of the analyte - claim 5
- C. the *complex* analyte - claim 6
- D. the *origin* of the complex analyte - claim 18

Traverse is on the grounds that there would be no undue effort for the Examiner to search the one claim in Group II.

Amendments to the Claims begin on page 2 and end on page 10.

Applicants' Remarks begin on page 11 and end on page 11.